Drug intelligence / Profile preview

Paidujiangzhi Capsules

Development stage: Unknown
Lead developer: Guangdong Pidi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Paidujiangzhi Capsules is a Traditional Chinese Medicine (TCM) developed and manufactured by Shenqi Pharmaceutical (Guizhou Shenqi Pharmaceutical). It is primarily indicated for the treatment of hyperlipidemia. Marketed as a "detoxifying and lipid-lowering" agent, the formulation is designed to regulate blood lipid levels and assist in the elimination of metabolic waste products from the body. In the context of Traditional Chinese Medicine, it is typically used to address patterns of phlegm-dampness and blood stasis. The product is approved by the National Medical Products Administration (NMPA) in China and is available as an oral capsule.

Brand names: Shenqi
Other names: Paidujiangzhi Jiaonang排毒降脂胶囊Detoxifying and Lipid-lowering Capsules

Beyond the preview

Go deeper on Paidujiangzhi Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paidujiangzhi Capsules.

Explore the full profile